Clinical analysis of drug treatment of Helicobacter pylori-related peptic ulcer

Objective To evaluate the efficacy of Rabeprazole and Omeprazole based triple therapy regimens in the treatment of Helicobacter pylori(Hp)-related peptic ulcer.Methods Eighty-six cases with documented peptic ulcer and Hp infection confirmed by endoscopic examination and rapid urease test were randomized to receive Rabeprazole(46 cases) or Omeprazole(40 cases) based triple therapy regimens for 14 days,including that Rabeprazole or Omeprazole 20 mg,Clarithromycin 0.5 g,and Amoxicillin 1.0 g,two times one day,followed by single use of Rabeprazole or Omeprazole 20 mg,one time per day for two months.Endoscopic examination and rapid urease test were repeated four weeks after the end of the treatment,and the degree of patients' symptomatic relief after medication were recorded.Results Symptomatic relief rate was 65.2%、93.5% in Rabeprazole group and 20.0%、45.0% in Omeprazole group at day 1 and 3,respectively,with a significance distinction between the two groups(P0.05).The ulcer healing rate was 95.7% in Rabeprazole group and 72.5% in Omeprazole group(P0.05).Hp eradication rate was 97.8% in Rabeprazole group and 90.0% in Omeprazole group,but there was no significant difference between the two groups(P0.05).Conclusion Rabeprazole based triple therapy regimen to treat Hp-associated peptic ulcers is the primary choice regarding ulcer healing rate and symptomatic relief.The preponderance of symptomatic relief and ulcus healing rate are obvious on Rabeprazole in comparison with Omeprazole.